Quanterix reported that second quarter revenues were impacted by a reduction in consumable revenue due to assay quality challenges and process improvement initiatives. The company is implementing a strategic business re-alignment plan, including a workforce reduction of approximately 130 employees, to improve its cost structure and focus on key platforms.
Second quarter revenues were impacted by a reduction in consumable revenue due to assay quality challenges.
The company announced a strategic business re-alignment plan, including restructuring.
The plan includes an assay redevelopment program to improve the ability to manufacture and deliver high-quality assays at scale.
The company expects to incur restructuring and related charges of approximately $7 million to $10 million in Q3 2022 and realize run-rate savings of approximately $25 million on an annualized basis.
Quanterix now expects its total 2022 revenue to be flat compared to 2021 and expects to return to double digit revenue growth by 2024.